---
title: "Roche H1 FY26 IFRS operating profit drops 6% to CHF 9.7 billion; sales fall 2% to CHF 30.4 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293561238.md"
description: "Roche reported a 6% drop in H1 FY26 IFRS operating profit to CHF 9.7 billion and a 2% sales decline to CHF 30.4 billion, primarily due to Swiss franc appreciation. Core operating profit fell 1%, while core diluted EPS slipped 2%. Pharmaceuticals and diagnostics sales decreased by 1% and 3% respectively. Despite these declines, Roche reaffirmed its 2026 outlook for mid-single-digit sales growth at constant exchange rates and high-single-digit core EPS growth."
datetime: "2026-07-23T05:13:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293561238.md)
  - [en](https://longbridge.com/en/news/293561238.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293561238.md)
generator: "portal-rs"
---

# Roche H1 FY26 IFRS operating profit drops 6% to CHF 9.7 billion; sales fall 2% to CHF 30.4 billion

-   Roche first-half sales fell 2% to CHF 30.36 billion as the Swiss franc’s appreciation weighed on reported results. \* IFRS operating profit dropped 6% to CHF 9.67 billion, while core operating profit edged down 1% to CHF 11.86 billion. \* Core diluted EPS slipped 2% to CHF 10.85; IFRS diluted EPS declined 8% on currency effects. \* Pharmaceuticals sales eased 1% to CHF 23.63 billion; Diagnostics sales declined 3% to CHF 6.74 billion. \* Roche confirmed its 2026 outlook for mid-single-digit sales growth at constant exchange rates and high-single-digit core EPS growth. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230100OMX\_\_\_\_\_CNEWS\_EN\_GNW1001214047\_en) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [Roche (SWX:ROG) Stock Margin Expansion To 19.6% Tests Bullish Earnings Narratives](https://longbridge.com/en/news/293799255.md)
- [IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer | IDYA Stock News](https://longbridge.com/en/news/296337883.md)
- [Roche (SWX:ROP) Wins Priority Review For Gazyva And Launches First Automated HDV Test](https://longbridge.com/en/news/292817546.md)
- [5-Roche confirms outlook despite Vabysmo miss, currency headwinds](https://longbridge.com/en/news/293605340.md)
- [Roche wins CE mark for Elecsys pTau217 Alzheimer’s blood test](https://longbridge.com/en/news/291878720.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**